Karen O'Hanlon | Chief Development Officer
Stablepharma

Dr. Karen O’Hanlon has worked in drug development for over 20 years and has a wealth of experience in vaccine development and clinical operations leadership. As Chief Development Officer at Stablepharma, she plays a pivotal role in advancing the Company’s mission to create fridge-free, thermostable vaccines and pharmaceutical products. Her leadership has been instrumental in the development of Stablepharma’s lead candidate, fridge-free Td vaccine which is currently being studied in a clinical trial in the UK. Prior to joining Stablepharma, Karen served as VP, Clinical Operations at Boyds where she was responsible for designing, planning and implementing clinical development programmes across Europe and ROW for a variety of products, including vaccines, gene therapies and biologicals. Prior to working at Boyds, Karen successfully built and exited from her own consultancy company. She also held earlier positions with hVivo, SRA Clinical Development, Medigene and Charles River. Over the years, Karen has contributed to the development of vaccines targeting a wide range of infectious diseases, including Stablepharma’s lead candidate Td vaccine,  influenza, RSV, HRV, HBV and COVID-19. Her multidisciplinary operational expertise spans preclinical, manufacturing, regulatory affairs and clinical development. Karen holds a PhD in Biochemistry from the University of Manchester and a BSc (hons) from the University of Glasgow.